The Effect of Mobile Lifestyle Intervention Combined with High-Protein Meal Replacement on Liver Function in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease: A Pilot Randomized Controlled Trial.
Eunbyul ChoSunwoo KimSoonkyu KimJu Young KimHwa Jung KimYumi GoYu Jung LeeHaesol LeeSiye GilSung Kwon YoonKeonho ChuPublished in: Nutrients (2024)
While many studies have explored dietary substitutes and mobile apps separately, a combined approach to metabolic dysfunction-associated steatotic liver disease (MASLD) has not been investigated. This study evaluated short-term mobile interventions coupled with partial meal replacement in patients with MASLD. Sixty adults with MASLD and a body mass index ≥25 kg/m 2 from a health examination center were randomized into an intervention group using a mobile app with partial meal replacements or a control group receiving standard educational materials. Liver enzyme levels, lipid profiles, and anthropometric measurements were assessed at baseline and after 4 weeks. Twenty-five participants in the intervention group and 24 in the control group completed the trial. Significant reductions were observed in the intervention group for alanine aminotransferase (-28.32 versus [vs.] -10.67, p = 0.006) and gamma-glutamyl transferase (-27.76 vs. 2.79, p = 0.014). No significant changes in aspartate aminotransferase, body weight, or waist circumference were noted in the intervention group. Four weeks of mobile lifestyle intervention incorporating partial meal replacements improved liver enzyme profiles in patients with MASLD. This strategy demonstrated the potential for mitigating elevated liver enzyme levels without altering body weight or waist circumference. Comprehensive and longer-term research is needed to substantiate and elaborate these preliminary outcomes.
Keyphrases
- body weight
- randomized controlled trial
- body mass index
- study protocol
- physical activity
- metabolic syndrome
- oxidative stress
- healthcare
- public health
- weight gain
- clinical trial
- phase iii
- mental health
- type diabetes
- open label
- phase ii
- preterm infants
- weight loss
- high resolution
- placebo controlled
- mass spectrometry
- social media
- climate change
- insulin resistance